Key result
Isolated cTnI elevation >0.45 ng/mL after PCI was not independently associated with increased all-cause mortality after adjusting for baseline risk factors.
Why the study?
Does isolated cTnI elevation after PCI predict all-cause mortality in patients with normal CK-MB?
Cohort (n=2,362)
Yes
Does isolated cTnI elevation after PCI predict all-cause mortality in patients with normal CK-MB?
Isolated cTnI elevation after PCI in the absence of CK-MB rise is associated with a modestly increased risk of death, but this is largely driven by baseline clinical risk factors rather than the troponin elevation itself.
Answers are grounded in this paper and cite their sources.
Isolated post-PCI cTnI elevation warrants no management change; leaves open its incremental prognostic value beyond baseline risk.
BACKGROUND: Mild elevations of cardiac troponin are frequent after percutaneous coronary intervention (PCI). Their prognostic value is uncertain in the absence of changes in creatine kinase-MB (CK-MB). METHODS AND RESULTS: We evaluated the relation between isolated elevations of cardiac troponin I (cTnI) and all-cause mortality. We studied 3494 consecutive patients who underwent PCI in 16 Italian tertiary cardiology centers. CK-MB and cTnI were analyzed in a central laboratory. Duration of follow-up was 2 years. The present analysis was restricted to 2362 patients with normal CK-MB and cTnI values at baseline and no CK-MB elevation after PCI. A rise in cTnI after PCI >0.15 ng/mL, the upper reference limit, was found in 932 patients (39.4%). A rise >0.45 ng/mL (>3×upper reference limit) was found in 467 patients (19.7%). Compared with patients with normal cTnI, those with cTnI elevation >0.15 ng/mL showed a slightly increased mortality (3.8% versus 2.6%; hazard ratio, 1.53; 95% confidence interval, 0.97 to 2.42; P=0.069). A cTnI elevation >0.45 ng/mL was associated with a higher risk of mortality (4.5% versus 2.7%; hazard ratio, 1.68; 95% confidence interval, 1.01 to 2.80; P=0.044), which, however, did not remain significant after adjustment for concomitant risk factors (hazard ratio, 1.45; 95% confidence interval, 0.86 to 2.46; P=0.162). Postprocedural cTnI elevation was associated with coronary and clinical features consistent with a worse risk profile. CONCLUSIONS: In the absence of a rise in CK-MB, elevated cTnI levels after PCI are associated with a modest increased risk of death. However, this is not independent of the concomitant adverse baseline clinical characteristics of these patients.
No takes yet. Share an insight, caveat, or question.
Cavallini et al. (2010) conducted a cohort in Percutaneous coronary intervention (PCI) (n=2,362). Isolated cTnI elevation >0.45 ng/mL after PCI vs. Normal cTnI was evaluated on All-cause mortality (HR 1.45, 95% CI 0.86-2.46, p=0.162). Isolated cTnI elevation >0.45 ng/mL after PCI was not independently associated with increased all-cause mortality after adjusting for baseline risk factors.
Synapse has enriched 10 related papers. Consider them for comparative context: